Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study - Wikidata - wikimedia - TriplyDB

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

http://www.wikidata.org/entity/Q29620647

about

Treatment of gastric cancer Molecular-targeted first-line therapy for advanced gastric cancer New advances in targeted gastric cancer treatment Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesis Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma Current and emerging therapies in unresectable and recurrent gastric cancer Emerging molecular classifications and therapeutic implications for gastric cancer Perioperative and Palliative Chemotherapy for Esophageal Cancer Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer Advanced gastric cancer: Current treatment landscape and future perspectives Novel targets in the treatment of advanced gastric cancer: a perspective review Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application Targeted therapy for advanced gastric cancer: A review of current status and future prospects Neo-adjuvant chemo(radio)therapy in gastric cancer: Current status and future perspectives Changing strategies for target therapy in gastric cancer Personalized medicine in gastric cancer: Where are we and where are we going?Advanced gastric cancer: What we know and what we still have to learn Gastric cancer: The times they are a-changin'Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological features Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma State of the art management of metastatic gastroesophageal cancer Molecular Dimensions of Gastric Cancer: Translational and Clinical Perspectives Neoadjuvant therapy for gastric cancer: current evidence and future directions Clinical utility of ramucirumab in advanced gastric cancer Ramucirumab: A New Therapy for Advanced Gastric Cancer Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Chemotherapy beyond second-line in advanced gastric cancer Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy Multimodal treatment of gastric cancer in the west: Where are we going?Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review Clinical practice guidelines for gastric cancer in Korea: an evidence-based approach Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity Anti-vascular endothelial growth factor therapy in breast cancer Targeted therapy in gastric cancer: personalizing cancer treatment based on patient genome Targeting receptor tyrosine kinases in gastric cancer Gastric cancer review

P2860

Q24602875-BFB85576-2DF1-4D0E-ABE4-C7272404E7C1 Q26471049-4246638D-688D-4507-A8C9-3CA96D428FD3 Q26738548-4DD076FF-513E-40B1-B25B-374A68BF816B Q26740812-C5627875-0D9B-4C32-AFA0-7EA5C70273F9 Q26741242-8255FC39-D171-4185-990B-9E64ADF8C420 Q26741530-80A479A6-64B4-46F0-BDA6-4A6AB7A820A1 Q26745453-CD358AC7-8358-4CA5-B798-3887E293EA76 Q26745525-DEAC9807-547B-4896-9864-748F53C9A4B3 Q26753865-2B808110-A392-4BFD-8F3A-D0B093C9D83C Q26764932-138616F9-2CEB-4A11-B70B-7D9A2BB26BAF Q26764934-E71C65C2-3616-43C8-97F6-0952449544AD Q26765208-B3EAF44C-54E0-4DA6-9563-8BB4ED2DC48A Q26765941-69A4F142-83F4-4A3A-9BDD-67B9709C60C2 Q26774138-AE242A95-A0A7-4475-B3F1-BF7D0C7915D6 Q26774283-F64D9C59-0F94-426C-A9BA-8AF381B69850 Q26774513-4C6B10AC-B966-4CC8-AF94-3F8CE15E2FEA Q26774521-71501386-A90B-427E-8887-C7995B993FAE Q26774528-0EAFEAB8-4467-4653-BF83-EDF774090D59 Q26776195-9C445589-9658-4EF5-B1E6-352BFA05F310 Q26776198-B928444D-B129-484E-B661-5944BE9C6052 Q26777690-05817F61-0E39-418A-A968-C537551BDD81 Q26779217-907DC3DA-824D-419A-B283-DB6B3FB4B015 Q26779725-814461A8-A80A-4CC5-B5CF-0036B2DE1292 Q26781043-5EA79B26-5202-42FE-AAFA-F3E3F452120F Q26785665-6E019D6D-BA78-4298-8745-2CE9B9549152 Q26785706-75F52AF9-F25D-438F-9413-F62885A685A4 Q26786618-AD9F130F-C2EE-4668-9D04-1B8643968DCB Q26798288-704F9145-E602-48C8-A95D-3D96E4419F3A Q26798400-935C5E2E-E115-4133-89C4-AA785D0B60A0 Q26798420-663B24E3-8666-4B6A-B59C-2F9E255AEDC8 Q26799748-647542D7-F263-49CA-994D-8DC241601214 Q26800355-663DF806-B62F-4C9C-BEF8-735C49433444 Q26801289-ECD87194-AC3F-40B3-B4E6-46BE5769DEF0 Q26824086-2002242C-E9F4-43F3-85CE-A6DACEBEA1F0 Q26828506-7F081AE5-47FD-40FB-9EDA-DAB4918D3767 Q26992272-E88E1574-6397-43FB-BDB1-6A6B781469D7 Q26999473-068CAFA1-A5C2-4871-9D91-9B77984A643B Q27008274-498EF7D6-7B23-4734-BCD9-D800E8FA3852 Q27013050-CFB4B39A-47AC-4CC1-A7A8-E237CDE43741 Q27025793-7FC0B02A-1F3F-4309-9283-4D078AC90B9A

P2860

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

http://www.wikidata.org/entity/Q29620647

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Bevacizumab in combination wit ...... ebo-controlled phase III study

@ast

Bevacizumab in combination wit ...... ebo-controlled phase III study

@en

type

label

Bevacizumab in combination wit ...... ebo-controlled phase III study

@ast

Bevacizumab in combination wit ...... ebo-controlled phase III study

@en

prefLabel

Bevacizumab in combination wit ...... ebo-controlled phase III study

@ast

Bevacizumab in combination wit ...... ebo-controlled phase III study

@en

P1433

Q29620647-459919F9-6C56-4A67-B059-68FA1736C983

P1476

Q29620647-C9200566-1C06-4817-BBC9-E2F21B7F6D10

P2093

Q29620647-2EB4FC25-6AC0-4D88-872C-00F3FC943963

Q29620647-489362E2-A703-4A3C-AA29-BAEC34048C77

Q29620647-76269D0F-4F51-4DC0-A11D-46DA8574DBD1

Q29620647-87EE4F46-DBDF-4B74-B9A8-07C484125A3A

Q29620647-A0DE544E-608E-44DF-B38C-F9D4EE100215

Q29620647-A30C3EEE-734B-4717-A5A9-97FFDDDAE062

Q29620647-B49831D1-D065-489F-9C82-827CE4AB3F86

Q29620647-C0052133-853E-423D-93FF-9B2B9D6830E2

Q29620647-D6578574-6081-4C50-904A-39A013F8F189

Q29620647-F62A835E-D7BC-48CB-94EF-BCDE0F1F4297

P304

Q29620647-CD71E737-C7DE-4AC3-806D-8DC7BBCBDC2D

P31

Q29620647-A7AD36E7-2955-46F4-9DC2-6104CB03DC38

P3181

Q29620647-2DCB3A0F-53C2-40C8-865A-2A3DDCCFE296

P356

Q29620647-E37F791A-D7E5-4633-9FD4-7C0F9197C448

P407

Q29620647-D2D9958B-5170-412A-A6EC-17C2E626F879

P433

Q29620647-27F4986D-A75E-403B-A7E9-740B000257B2

P478

Q29620647-909307CB-8609-4489-B271-92BCA0879249

P50

Q29620647-D5005CFD-8581-49FA-A009-6A9F94ADB904

P577

Q29620647-920482CA-6F6F-47EF-B4C8-E49F40E9959F

P698

Q29620647-BC9EA86E-EBEF-4638-9FFF-39C6C60BB41D

P921

Q29620647-20B2AA6D-9E34-47E9-9326-29B749D33D70

Q29620647-57015FE4-E775-45A9-8786-D8848399BA94

Q29620647-C3770FAB-FD58-4276-BA45-8D6613A1BB7F

P3181

P356

JCO.2011.36.2236

P1433

Journal of Clinical Oncology

P1476

Bevacizumab in combination wit ...... ebo-controlled phase III study

@en

P2093

Akira Sawaki

http://www.w3.org/2001/XMLSchema#string

Atsushi Ohtsu

http://www.w3.org/2001/XMLSchema#string

Bernd Langer

http://www.w3.org/2001/XMLSchema#string

Eric Van Cutsem

http://www.w3.org/2001/XMLSchema#string

Ho Yeong Lim

http://www.w3.org/2001/XMLSchema#string

Jian Wu

http://www.w3.org/2001/XMLSchema#string

Manish A Shah

http://www.w3.org/2001/XMLSchema#string

Michal Starnawski

http://www.w3.org/2001/XMLSchema#string

Sook Ryun Park

http://www.w3.org/2001/XMLSchema#string

Yasuhide Yamada

http://www.w3.org/2001/XMLSchema#string

P304

3968-3976

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

181173

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2011.36.2236

http://www.w3.org/2001/XMLSchema#string

P407

P433

30

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-08-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21844504

http://www.w3.org/2001/XMLSchema#string

P921